Senate Commerce Committee advances bipartisan gene-synthesis screening bill
Published · Updated
What happened
The Senate Commerce Committee approved legislation that would mandate screening of gene synthesis orders and customers by providers operating in the United States.
Why it matters
Committee passage creates a nearer-term path for federal requirements in a sector where screening practices have been uneven and partly voluntary. If enacted, the bill would change compliance expectations for biotech suppliers and could influence procurement, enforcement, and international standard-setting discussions.
On November 18, the U.S. Senate Commerce, Science, and Transportation Committee passed the Biosecurity Modernization and Innovation Act, a bipartisan bill introduced by Senators Tom Cotton and Amy Klobuchar. The measure would require gene synthesis providers to screen sequence orders and customers to reduce access to hazardous genetic material by malicious actors. The committee action moves the proposal from concept to a live legislative vehicle that could shape federal standards for a fast-growing biotechnology service market.
Watch for
Senate Commerce, Science, and Transportation Committee publication of bill text or report language on provider screening obligations by 2026-11-22 Senate Majority Leader statement or floor schedule showing whether the bill will receive Senate floor time by 2026-11-22 White House Office of Science and Technology Policy acknowledgement of the committee-passed bill and its relation to existing federal biosecurity guidance by 2026-11-22 Industry Biotechnology Innovation Organization or major U.S. gene synthesis providers public position on mandatory customer screening compliance costs by 2026-11-22
Sources
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made